Noxopharm: Anti-cancer patents granted 

Listen to ASX-listed Noxopharm CEO Dr Graham Kelly talk to Matt Birney on the Bulls N’ Bears report about how Noxopharm has protected its potentially lucrative looking biotechnology that it says aims to boost the effectiveness of existing anti-cancer treatments.

Noxopharm: Anti-cancer patents granted 
Listen to ASX-listed Noxopharm CEO Dr Graham Kelly talk to Matt Birney on the Bulls N&rsquo; Bears report about how Noxopharm has protected its potentially lucrative looking biotechnology that it says aims to boost the effectiveness of existing anti-cancer treatments.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N’ Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia’s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Matt Birney and Bulls N' Bears sit at the epicentre of the small cap ASX-listed company space in Perth and Western Australia. Bulls N&rsquo; Bears covers public company news, views and CEO interviews across a number of main stream media platforms in WA. Its financial markets followers, who come from all four corners of the globe, are looking to zero in on Western Australia&rsquo;s unique international status as the most prolific developer of small capped publicly listed companies in the world.

Advertisement